| Literature DB >> 23955266 |
Wanda Lattanzi1, Valentina Corvino, Valentina Di Maria, Fabrizio Michetti2, Maria Concetta Geloso3.
Abstract
Trimethyltin (TMT) is an organotin compound exhibiting neurotoxicant effects selectively localized in the limbic system and especially marked in the hippocampus, in both experimental animal models and accidentally exposed humans. TMT administration causes selective neuronal death involving either the granular neurons of the dentate gyrus or the pyramidal cells of the Cornu Ammonis, with a different pattern of localization depending on the different species studied or the dosage schedule. TMT is broadly used to realize experimental models of hippocampal neurodegeneration associated with cognitive impairment and temporal lobe epilepsy, though the molecular mechanisms underlying the associated selective neuronal death are still not conclusively clarified. Experimental evidence indicates that TMT-induced neurodegeneration is a complex event involving different pathogenetic mechanisms, probably acting differently in animal and cell models, which include neuroinflammation, intracellular calcium overload, and oxidative stress. Microarray-based, genome-wide expression analysis has been used to investigate the molecular scenario occurring in the TMT-injured brain in different in vivo and in vitro models, producing an overwhelming amount of data. The aim of this review is to discuss and rationalize the state-of-the-art on TMT-associated genome wide expression profiles in order to identify comparable and reproducible data that may allow focusing on significantly involved pathways.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23955266 PMCID: PMC3759937 DOI: 10.3390/ijms140816817
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Overview of microarray-based genome-wide expression analysis in the in vivo trimethyltin (TMT)-induced models of neurodegeneration.
| Model animal (No. of samples per experimental group) | Age at treatment | Rodent strain – Animal gender | TMT dosage (administration route) | Hippocampal tissue specimen | Tested time points (post-TMT treatment) | Reference |
|---|---|---|---|---|---|---|
| Mouse ( | Adult | B6, 129 Nfkb1 tmlBal B6,129 2/J – F/M | p-50 null: 2.0 mg/kg; Non transgenic: 2.25 mg/kg | Whole hippocampus | 7 days | [ |
| Mouse ( | P21 | CD-1 – M | 3 mg/Kg (i.p.) | Microdissected DG and CA | 6–18 h | [ |
| Mouse ( | P120 | CD-1 – M | 2.4 mg/Kg (i.p.) | Whole hippocampus | 24 h | [ |
| Mouse ( | P21 1 year | CD-1 – M | 2.3 mg/Kg (i.p.) | Microdissected SGZ | 48 h | [ |
| Rat ( | 6 weeks | Sprague–Dawley – M | 9 mg/Kg (oral) | Whole hippocampus | 2–5 days | [ |
| Rat ( | 6 weeks | Long –Evans – F/M | 8.0 mg/Kg (i.p.) | Whole hippocampus | 3–5 days | [ |
F: female; M: male; F/M: both sexes.
Figure 1A schematic representation of TMT-induced gene activation in (a) mice; (b) rats; and (c) PC12 cells. (a) Results obtained in mice indicate the significant and early involvement of genes related to apoptosis, neuroinflammation and neurogenesis; (b) The studies performed in the rat model reflect an involvement of calcium homeostasis dysregulation and mitochondrial damage. The contribution of the authophagic pathway may be hypothesized, but genes related to neuroinflammation are not unambiguously modulated in the early phases of TMT-induced neurodegeneration; and (c) the study performed in PC12 cells evidences the activation of oxidative metabolism of glucose, cholesterol and fatty acids, along with the early activation of genes involved in apoptosis and stress-related pathways.